5407012026-04-012026-06-305407012026-04-012026-06-30in-capmkt:OtherExpenses1Member5407012026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15407012026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25407012026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares540701DCALNAINE385W01011Dishman Carbogen Amcis LimitedMain BoardEquity2026-04-012027-03-312026-08-142026-08-10INRCroresQuarterlyFirst quarterSingle segmentContract Development and Manufacturing Organisation (CDMO), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc.2026-08-1414:00:002026-08-1419:00:00Not applicablefalsefalseNot Applicable for the Quarter2026-04-012026-06-30UnauditedStandalone5708000001889000007597000001539000000-169000002105000002171000001537000003415000001059800000-300100000-16900000-3170000000-77900000-779000000-2391000000000-239100000261600000225000003136000002-1.52-1.5200-1.52-1.520.00170.00210.0085Notes: <br /> <br /> 1. The Financial results (standalone and consolidated) have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 14th August, 2026. <br /> <br /> 2. These financial results (standalone and consolidated) have been prepared in compliance with Ind AS, as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable. <br /> <br /> 3. Statutory Auditors have carried out limited review of standalone as well as consolidated financial results of the Company for the quarter ended 30th June, 2026. <br /> <br /> 4. The figures for the previous quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the financial year 2025-26. <br /> <br /> 5. The excess amount of consideration payable over net assets acquired had been recorded as goodwill amounting to INR 1,326.86 crores in the amalgamation held between Dishman Pharmaceuticals and Chemical Limited and Dishman Care Limited into Dishman Carbogen Amcis Limited accounted in the year 2016-17 as per the Scheme of Amalgamation approved by the Hon’ble High Court, Gujarat, which is different from Ind AS 103 “Business Combinations”. The same was represented by underlying intangible assets acquired on amalgamation and was being amortized over the period of 15 years from the Appointed Date i.e. 1st January, 2015. <br /> <br /> The value of the Goodwill had already been reduced by Rs. 641.28 crores by March 31, 2022, the Board re-assessed the life of the Goodwill looking at the expected growth and benefits available to the Company. Taking a conservative view, considering the possible impact of COVID and the delay in clearance of EDQM observations for the Bavla site, the Board revised the useful life of goodwill to 15 years starting from 1st April 2022 instead of the remainder useful life of 7 years, with a next time frame to further re-assess the same after COVID and major regulatory clearance. <br /> <br /> After successfully completing all major regulatory audit in last six to twelve months and the impact of COVID having phased out, the Board now expects the performance of the India business to improve and the current value of Goodwill as on 1st April, 2024 of INR 594.17 Crores as reflecting a fair value of the intangible assets for a sustainably long period. The robust outlook in the CDMO sector also supports the company’s path for growth. <br /> <br /> Considering all above factors, Board has decided to keep the current goodwill value of INR 594.17 Crores till perpetuity i.e. 99 years considering life with effect from 1st January, 2015. This change in estimate of life will be applicable prospectively over the remaining useful life starting from 1st April, 2024. The goodwill will tested for impairment at the end of every financial year. <br /> <br /> Had the goodwill not been amortized as required under Ind AS 103, the Depreciation and Amortization expense for the quarter ended 30th June, 2026, 31st March, 2026, 30th June, 2025 and for the year ended 31st March, 2026 would have been lower by INR 1.65 crores, INR 1.63 crores, INR 1.65 crores and INR 6.60 crores respectively, and the Profit Before Tax for the corresponding periods would have been higher by an equivalent amount. <br /> <br /> 6. The financial results are available for perusal on the Company’s website: www.imdcal.com as well as on the Stock Exchange’s websites i.e. on www.bseindia.com and www.nseindia.com. <br /> <br /> 7. Group is required to disclose segment information based on the ‘management approach’ as defined in Ind AS 108- Operating Segments, which is how the Chief Operating Decision Maker (CODM) evaluates the Group’s performance and allocates resources based on the analysis of the various performance indicators. CODM reviews the results of the Group engaged in the business of Contract Development and Manufacturing Organisation (CDMO), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc. Accordingly, Group as a whole is a single segment. The information as required under Ind AS 108 is available directly from the financial statements, hence no separate disclosure has been made. <br /> <br /> 8. Consolidated financial results comprise the results of the parent Company, Dishman Carbogen Amcis Limited and its subsidiaries (together referred as “the Group”) viz. Dishman CARBOGEN AMCIS (Europe) Ltd., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd, CARBOGEN AMCIS Holdings AG., Switzerland; CARBOGEN AMCIS (Shanghai) Co. Ltd.,; CARBOGEN AMCIS BV, Carbogen Amcis Ltd., U.K., CARBOGEN AMCIS AG (“CGAM AG”), Switzerland, CARBOGEN AMCIS SAS, Dishman Carbogen Amcis (Japan) Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd.,; Dishman Biotech Ltd.; CARBOGEN AMICS Innovations AG.; DISHMAN CARBOGEN AMCIS AG.; CARBOGEN AMCIS Real Estate, Dishman Medicare Limited (formerly known as Visible Investment Limited) and Dishman Carbogen AMCIS Technology AG. <br /> <br /> 9. Exceptional items for the quarter include a charge of Rs.1.69 crores representing transaction costs for a proposed QIP of equity shares. While these expenses were incurred in the previous financial year, they have been written off during the current quarter following management's decision to abandon the issue due to adverse market conditions and an altered fundraising plan. As these costs are material, non-operating, and do not relate to normal current-period operations, they are presented separately. <br /> <br /> 10. (a) the Company had issued senior, secured, rated, listed, taxable, redeemable, transferable, non-convertible debentures of INR 49.99 crores (Indian Rupees Forty Nine Crore and Ninety Nine Lakh only) having ISIN INE385W07034 and has maintained 100% security cover of the principal and interest amount as on 30th June, 2026 by creating first ranking exclusive charge on identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. There was no interest or principal payment falling due during the quarter ended 30th June, 2026 and the Company has duly paid the full principal along with interest payment during the period from 13th July, 2026 to 15th July, 2026 for which due date was 17th July, 2026. <br /> <br /> (b) the Company had issued Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of INR 50.00 crores (Indian Rupees Fifty Crores only) having ISIN INE385W07042 and has maintained 100% security cover of the principal and interest amount as on 30th June, 2026 by creating first ranking exclusive charge on identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. Quarterly interest payment due on 26th June, 2026 has been paid during 23rd June, 2026 to 26th June, 2026 and there was no principal payment falling due during the quarter ended 30th June, 2026. <br /> <br /> (c) the Company had issued Senior, Secured, Rated, Listed, Taxable, Redeemable, Transferable, Non-Convertible Debentures of INR 50.00 crores (Indian Rupees Fifty Crores only) having ISIN INE385W07059 and has maintained 100% security cover of the principal and interest amount as on 30th June, 2026 by creating charge on (i) identified properties of the Company, (ii) identified properties of the Promoter of the Company viz. Mr. Arpit J. Vyas and (iii) identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. Quarterly payment towards interest and partial redemption of Principal amount on face value basis due on 20th April, 2026 has been paid on 18th April, 2026. <br /> <br /> 11. The Company has issued and allotted 1800 (One Thousand and Eight Hundred) Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures denominated in Indian Rupees ("INR"), having a face value of INR 1,00,000 (Indian Rupees One Lakh) each and an aggregate nominal value of INR 18,00,00,000 (Indian Rupees Eighteen Crores only) on a private placement basis (“Debentures”) on 9th June, 2026 as approved by the Board and has received Listing and trading approval from BSE Limited vide its notice dated 11th June, 2026. There is no deviation in use of proceeds from the objects stated in the Disclosure Document. <br /> <br /> The Secured Non-convertible Debentures of the Company aggregating INR 18.00 crores (Indian Rupees Eighteen Crores only) as on 30th June, 2026 are secured by creating charge on identified properties of the Promoter of the Company viz. Mr. Arpit J. Vyas . The asset cover in respect of the Secured Debentures of the Company as on 30th June, 2026 is 100% of the principal and interest amount of the said Secured Non-convertible Debentures. <br /> <br /> <br /> Statement of utilization of issue proceeds: (INR in Crores) <br /> <br /> (1) Name of the Issuer: Dishman Carbogen Amcis Ltd <br /> (2) ISIN: INE385W07067 <br /> (3) Mode of Fund Raising (Public issues/ Private placement): Private Placement <br /> (4) Type of instrument: Secured Non convertible Debentures <br /> (5) Date of raising funds: 09-06-2026 <br /> (6) Amount Raised: 18.00 <br /> (7) Funds utilized: 18.00 <br /> (8) Any deviation (Yes/ No): No <br /> (9) If 8 is Yes, then specify the purpose of for which the funds were utilized: NA <br /> (10) Remarks, if any: None <br /> <br /> Statement of deviation/ variation in use of Issue proceeds: <br /> <br /> Particulars: Remarks <br /> 1. Name of listed entity: Dishman Carbogen Amcis Ltd <br /> 2. Mode of fund raising: Private Placement <br /> 3. Type of instrument: Secured Non-convertible Debentures <br /> 4. Date of raising funds: 09-06-2026 <br /> 5. Amount raised: INR 18.00 Crores <br /> 6. Report filed for quarter ended: 30/06/2026 <br /> 7. Is there a deviation/ variation in use of funds raised?: No <br /> 8. Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?: No <br /> 9. If yes, details of the approval so required?: NA <br /> 10. Date of approval: NA <br /> 11. Explanation for the deviation/ variation: NA <br /> 12. Comments of the audit committee after review: This statement as on June 30, 2026, was placed before the Audit Committee at its meeting held on August 14, 2026. The Committee noted the same. <br /> 13. Comments of the auditors, if any: NA <br /> 14. Objects for which funds have been raised and where there has been a deviation/ variation, in the following table: <br /> <br /> a. Original object: The proceeds of the issue has been utilized for the following purposes: <br /> 1. Capital expenditure requirements of the company, including maintenance capital expenditure and reimbursement of capital <br /> expenditure incurred; <br /> 2. Working capital requirements of the company; <br /> 3. Repayment of existing Financial indebtedness of the company; <br /> 4. General corporate purposes; <br /> 5. Costs and expenses in relation to the issuance of Debentures <br /> 6. Such other purposes as mutually agreed <br /> <br /> There is no deviation / variation, in the utilization. <br /> <br /> b. Modified object, if any: NA <br /> c. Original allocation: NA <br /> d. Modified allocation, if any: NA <br /> e. Funds utilised: NA <br /> f. Amount of deviation/ variation for the quarter according to applicable object (in Rs. crore and in %): NA <br /> g. Remarks, if any: NA <br /> <br /> Deviation could mean: <br /> a. Deviation in the objects or purposes for which the funds have been raised. <br /> b. Deviation in the amount of funds actually utilized as against what was originally disclosed. <br /> <br /> <br /> <br /> 12. The company has decided to exercise the option available under Section 200 of the Income Tax Act, 2025, and accordingly, the provisions of the said section shall be applicable to the company with effect from FY 2026–27 onwards. Hence, effective tax rate has changed. <br /> <br /> 13. The previous quarter / year figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable. <br /> <br /> On behalf of the Board of Directors <br /> <br /> <br /> Arpit Vyas <br /> Place: Vitznau Global Managing Director <br /> Date: 14th August, 2026 DIN - 01540057 <br /> Other Expenditure341500000Re measurement gains/ (Losses) on defined benefit plans0Changes in fair value of FVTOCI equity instruments000Foreign exchange fluctuation in respect of cash flow hedge34960000034960000088000000261600000